Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022

INTRODUCTION: Nirmatrelvir/ritonavir (Paxlovid®) is currently one of the few therapeutic options for coronavirus disease 2019 (COVID-19) curative treatment in non-oxygen-requiring adult patients at-high risk of progressing to severe disease. This recently approved boosted antiviral therapy presents...

Descripción completa

Detalles Bibliográficos
Autores principales: Bihan, Kevin, Lipszyc, Lorène, Lemaitre, Florian, Dautriche, Anne, Fédrizzi, Sophie, Atzenhoffer, Marina, Vitores, Aurélie, Page, Annabelle, Lebrun-Vignes, Bénédicte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2023
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990891/
https://www.ncbi.nlm.nih.gov/pubmed/37012153
http://dx.doi.org/10.1016/j.therap.2023.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990891/
https://www.ncbi.nlm.nih.gov/pubmed/37012153
http://dx.doi.org/10.1016/j.therap.2023.03.001

Ejemplares similares